Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

4.

Treatment of unprotected left main disease with drug-eluting stents in patients at high risk for coronary artery bypass grafting.

Barlis P, Horrigan M, Elis S, Chan R, Wong M, Farouque O, Proimos G, Ajani AE, Clark DJ.

Cardiovasc Revasc Med. 2007 Apr-Jun;8(2):84-9.

PMID:
17574165
5.

A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents.

Rathore S, Kinoshita Y, Terashima M, Katoh O, Matsuo H, Tanaka N, Kimura M, Tsuchikane E, Nasu K, Ehara M, Asakura K, Asakura Y, Suzuki T.

EuroIntervention. 2010 Feb;5(7):841-6.

PMID:
20142201
6.

5-year outcomes following percutaneous coronary intervention with drug-eluting stent implantation versus coronary artery bypass graft for unprotected left main coronary artery lesions the Milan experience.

Chieffo A, Magni V, Latib A, Maisano F, Ielasi A, Montorfano M, Carlino M, Godino C, Ferraro M, Calori G, Alfieri O, Colombo A.

JACC Cardiovasc Interv. 2010 Jun;3(6):595-601. doi: 10.1016/j.jcin.2010.03.014.

7.

Comparison of drug-eluting stent with bare metal stent for distal de novo unprotected left main coronary artery stenosis. A propensity score-matched cohort study.

Hsueh SK, Wu CJ, Fang HY, Hsieh YK, Fang CY, Chen CJ, Chen SM, Yang CH, Yip HK, Chen MC, Fu M, Cheng CI.

Circ J. 2011;75(2):290-8. Epub 2010 Dec 10.

8.

Outcomes of percutaneous coronary intervention in intermediate coronary artery disease: fractional flow reserve-guided versus intravascular ultrasound-guided.

Nam CW, Yoon HJ, Cho YK, Park HS, Kim H, Hur SH, Kim YN, Chung IS, Koo BK, Tahk SJ, Fearon WF, Kim KB.

JACC Cardiovasc Interv. 2010 Aug;3(8):812-7. doi: 10.1016/j.jcin.2010.04.016.

9.

Combined assessment of myocardial perfusion and late gadolinium enhancement in patients after percutaneous coronary intervention or bypass grafts: a multicenter study of an integrated cardiovascular magnetic resonance protocol.

Bernhardt P, Spiess J, Levenson B, Pilz G, Höfling B, Hombach V, Strohm O.

JACC Cardiovasc Imaging. 2009 Nov;2(11):1292-300. doi: 10.1016/j.jcmg.2009.05.011.

10.

The Bypass Angioplasty Revascularization in Type 1 and Type 2 Diabetes Study: 5-year follow-up of revascularization with percutaneous coronary intervention versus coronary artery bypass grafting in diabetic patients with multivessel disease.

Kapur A, Bartolini D, Finlay MC, Qureshi AC, Flather M, Strange JW, Hall RJ.

J Cardiovasc Med (Hagerstown). 2010 Jan;11(1):26-33. doi: 10.2459/JCM.0b013e328330ea32.

PMID:
19797974
11.

Impact of diabetes mellitus on patients with unprotected left main coronary artery lesion disease treated with either percutaneous coronary intervention or coronary-artery bypass grafting.

Luo Y, Yu X, Chen F, Du X, He J, Gao Y, Zhang X, Zhang Y, Ren X, Lv S, Ma C.

Coron Artery Dis. 2012 Aug;23(5):322-9. doi: 10.1097/MCA.0b013e3283564961.

PMID:
22750912
12.

The role of drug-eluting balloons alone or in combination with drug-eluting stents in the treatment of de novo diffuse coronary disease.

Costopoulos C, Latib A, Naganuma T, Sticchi A, Figini F, Basavarajaiah S, Carlino M, Chieffo A, Montorfano M, Naim C, Kawaguchi M, Giannini F, Colombo A.

JACC Cardiovasc Interv. 2013 Nov;6(11):1153-9. doi: 10.1016/j.jcin.2013.07.005.

13.

Provisional stenting for multivessel PCI.

Han B, Liu L, Aboud M, Nahir M, Hasin Y.

Int J Cardiovasc Intervent. 2005;7(1):46-51.

PMID:
16019615
14.

3-year clinical outcome of patients with chronic total occlusion treated with drug-eluting stents.

De Felice F, Fiorilli R, Parma A, Nazzaro M, Musto C, Sbraga F, Caferri G, Violini R.

JACC Cardiovasc Interv. 2009 Dec;2(12):1260-5. doi: 10.1016/j.jcin.2009.09.013.

15.

Percutaneous coronary intervention of moderate to severe calcified coronary lesions: insights from the National Heart, Lung, and Blood Institute Dynamic Registry.

Bangalore S, Vlachos HA, Selzer F, Wilensky RL, Kip KE, Williams DO, Faxon DP.

Catheter Cardiovasc Interv. 2011 Jan 1;77(1):22-8. doi: 10.1002/ccd.22613.

16.

Fractional flow reserve guided coronary revascularization in drug-eluting era in Thai patients with borderline multi-vessel coronary stenoses.

Angkananard T, Wongpraparut N, Tresukosol D, Panchavinin P.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S25-32.

PMID:
21721425
17.

The effect of drug eluting stents on cardiovascular events in patients with intermediate lesions and borderline fractional flow reserve.

Lavi S, Rihal CS, Yang EH, Fassa AA, Elesber A, Lennon RJ, Mathew V, David HR Jr, Lerman A.

Catheter Cardiovasc Interv. 2007 Oct 1;70(4):525-31.

PMID:
17896397
18.

Comparison of percutaneous coronary intervention with bare-metal and drug-eluting stents for cardiac allograft vasculopathy.

Lee MS, Kobashigawa J, Tobis J.

JACC Cardiovasc Interv. 2008 Dec;1(6):710-5. doi: 10.1016/j.jcin.2008.10.001.

19.

Twelve months clinical outcome of drug-eluting stents implantation or coronary artery bypass surgery for the treatment of diabetic patients with multivessel disease.

Qiao Y, Ma C, Nie S, Liu X, Kang J, Lv Q, Du X, Hu R, Zhang Y, Jia C, Liu X, Dong J, Chen F, Zhou Y, Lv S, Huang F, Gu C, Wu X.

Clin Cardiol. 2009 Aug;32(8):E24-30. doi: 10.1002/clc.20413.

20.

Left main coronary artery stenosis: a meta-analysis of drug-eluting stents versus coronary artery bypass grafting.

Athappan G, Patvardhan E, Tuzcu ME, Ellis S, Whitlow P, Kapadia SR.

JACC Cardiovasc Interv. 2013 Dec;6(12):1219-30. doi: 10.1016/j.jcin.2013.07.008. Review.

Supplemental Content

Support Center